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Opioids alter paw placement during walking,
confounding assessment of analgesic efficacy in a
postsurgical pain model in mice
Victoria E. Bringsa, Maria A. Paynea, Robert W. Gereau IVa,b,c,*

Abstract
Introduction: Hind paw–directed assays are commonly used to study the analgesic effects of opioids in mice. However, opioidinduced hyperlocomotion can obscure results of such assays.
Objectives: We aimed to overcome this potential confound by using gait analysis to observe hind paw usage during walking in mice.
Methods: We measured changes in the paw print area after induction of postsurgical pain (using the paw incision model) and
treatment with oxycodone.
Results: Paw incision surgery reduced the paw print area of the injured hind paw as mice avoided placing the incised section of the
paw on the floor. Surprisingly, oxycodone caused a tiptoe-like gait in mice, reducing the paw print area of both hind paws. Further
investigation of this opioid-induced phenotype revealed that analgesic doses of oxycodone or morphine dose-dependently reduced
the hind paw print area in uninjured mice. The gait changes were not dependent on opioid-induced increases in the locomotor
activity; speed and paw print area had no correlation in opioid-treated mice, and other analgesic compounds that alter locomotor
activity did not affect the paw print area.
Conclusion: Unfortunately, the opioid-induced “tiptoe” gait phenotype prevented gait analysis from being a viable metric for
demonstrating opioid analgesia in injured mice. However, this work reveals an important, previously uncharacterized effect of
treatment with analgesic doses of opioids on paw placement. Our characterization of how opioids affect gait has important
implications for the use of mice to study opioid pharmacology and suggests that scientists should use caution when using hind
paw–directed nociceptive assays to test opioid analgesia in mice.
Keywords: Opioid, Oxycodone, Gait, Paw incision, Postsurgical injury, Mouse behavior

1. Introduction
Mice are widely used to study the behavioral effects of opioids,
including analgesia, dependence, and respiratory depression.8,13,29,32 Antinociceptive properties of mu-opioid agonists
are often tested in mice using reflexive hot-plate or tail-flick
assays.13,32,36 To study opioid analgesia in tissue or nerve injury
models in mice, injury-induced sensitization and its reversal with
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opioids are assessed by measuring sensitivity to stimuli directed
to the affected body region, which is often the hind paw.12 Most
commonly used hind paw–directed assays entail the quantification of a withdrawal response to the application of noxious stimuli
to the hind paw.5,12 These assays reflect evoked responses to an
exogenous stimulus and do not reflect naturalistic pain behaviors.12,33 They also measure reflexive withdrawal responses,
which may not accurately represent pain or the effects of
analgesia.15,19 In addition to having potentially flawed face
validity, hind paw–directed evoked pain assays are particularly
challenging to perform on opioid-treated mice because of
increases in the locomotor activity induced by mu-opioid
agonists.10,35,36
Because of the shortcomings of evoked withdrawal tests,
alternative approaches are needed to assess opioid analgesia in
mice. We and others have used a variety of nonreflexive
behavioral assays to assess pain sensitivity and analgesia in
mice, such as voluntary wheel running, home cage lid hanging,
and gait analysis.22,31,33,38,42 The Noldus CatWalk XT gait
analysis system was originally designed to quantify deficits in
motor function seen in models of spinal cord injury.16,17 More
recently, others have used this system to demonstrate the effects
of injury and analgesic treatment on gait in rats and mice.1,22,31,38

www.painreportsonline.com

1

2

·

PAIN Reports®

V.E. Brings et al. 7 (2022) e1035

Downloaded from http://journals.lww.com/painrpts by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywC
X1AWnYQp/IlQrHD3i3D0OdRyi7TvSFl4Cf3VC4/OAVpDDa8KKGKV0Ymy+78= on 09/14/2022

To achieve our goal of measuring behavior affected by postsurgical injury and reversed by opioids in mice, we used the
CatWalk gait analysis system to observe hind paw usage during
voluntary walking behavior. Gait analysis provides a means of
assessing hind paw usage with a nonreflexive behavioral assay
that would be technically feasible with a hyperactive mouse.
Using the CatWalk system, we measured changes in the paw
print area after induction of postsurgical pain with the paw incision
injury model and treatment with oxycodone in mice. We
hypothesized that paw incision injury would produce alterations in
paw placement during walking that could be reversed with
oxycodone. We found that paw incision injury reduces the print
area of the injured paw. Surprisingly, however, analgesic doses of
oxycodone induced a “tiptoe” phenotype that dose dependently
reduced the print area of all paws. The reduction in the paw print
area was independent of walking speed and was specific to opioids
(oxycodone and morphine), as mice treated with the nonopioid
analgesics fenobam and D9-tetrahydrocannibinol did not show
altered paw print area. Overall, this work demonstrates the effect of
opioid treatment on paw usage and has implications for the use of
hind paw–directed sensory assays in opioid-treated mice.

2. Methods
2.1. Animals
All procedures used in this study were approved by the
Institutional Animal Care and Use Committee at Washington
University in St. Louis School of Medicine. C57BL/6 mice bred
in-house were given food and water ad libitum in a facility with a
12-h light:dark cycle. Behavior was tested during the light
phase at 8 to 12 weeks of age. Male and female mice were
tested separately. Animals were randomly assigned to each
condition. Different test groups (injury and drug treatment) had
equal average weights. Cages had mixes of animals from
different test groups, group-housed with 3 to 5 mice per cage.
Experimenters were blinded to drug treatment or surgical
condition until data were analyzed.

isoflurane anesthesia, the surface of the right hind paw was
sterilized and a 5-mm incision was made through the skin starting
2 mm from the heel using a type 11 scalpel blade (McKesson,
Richmond, VA). The flexor digitorum brevis muscle was pulled up
to isolate, and an approximately 3-mm vertical incision was made
through the muscle. The skin was closed with 2 6-0 silk sutures
(Ethicon, Guaynabo, Puerto Rico). Antibiotic ointment (McKesson) was applied. For the sham surgery, mice were anesthetized,
the right hind paw was sterilized, and sutures were applied, but
no incisions were made.
2.4. Electronic von Frey
Mechanical allodynia was measured using an electronic von Frey
anesthesiometer (IITC Life Science, Woodland Hills, CA).34 Mice
were placed on an elevated stainless steel mesh platform and
isolated in individual acrylic containers. Mice were acclimated for
at least 1 day and were habituated for 1 hour before testing.
Alternating hind paws, 5 measurements were taken per paw, with
at least 1 minute between measurements for a single paw. On the
day of testing postsurgery, approximately 15 minutes after
acquiring baseline data, the animals were injected with the test
compound and tested again for postdrug responses 30 minutes
later. The blunt tip of the anesthesiometer was applied to the hind
paw approximately 4 to 5 mm from the heel (corresponding to the
space between the 2 sutures on the hind paw in sham and injured
animals, Fig. 1A), and the amount of force applied before the
animal withdrew their hind paw was recorded. Of the 5
measurements taken per paw, the highest and lowest measurements were excluded, and the remaining 3 measurements were
averaged.

2.2. Drugs
Oxycodone (USP, Rockville, MD) was dissolved in saline (0.9%
NaCl; Hospira, Lake Forest, IL), and morphine (10 mg/mL;
Hikma, Eatontown, NJ) was diluted in saline; each was delivered
s.c. in a volume of 5 mL/kg body weight. D9-tetrahydrocannabinol (THC; 200 mg/mL; National Institute on Drug Abuse Drug
Supply Program, Bethesda, MD) was diluted with 95% ethanol
followed by a mix of Kolliphor EL (Sigma-Aldrich, St. Louis, MO)
and saline to achieve a final vehicle of 5% 95% ethanol, 5%
Kolliphor EL, and 90% 0.9% saline, delivered s.c. in a volume of 5
mL/kg. Fenobam (SCYNEXIS, Durham, NC) was dissolved in a
vehicle of 100% DMSO (Sigma-Aldrich), delivered i.p. in a volume
of 20 mL. For all drugs, testing was performed within 30 minutes
(30–60 minutes postdelivery of oxycodone, morphine, and D9THC; 5–35 minutes postdelivery of fenobam). Doses were
chosen based on previous reports that analgesia and/or
antinociception can be achieved at the indicated doses for
oxycodone,2,14,26,30,39,40 morphine,26,30 fenobam,25,27,28 and
D9-THC.3,9,23 Mice were returned to home cage after injection
and were kept there until testing.
2.3. Paw incision surgery
Paw incision surgery was performed on the right hind paw (Fig.
1A), following previous published procedures.11,41 While under

Figure 1. Diagram of the hind paw showing locations used for sensory testing
and incision injury. (A) An outline of a mouse hind paw showing circles that
correspond to raised sections of the foot pad (brown). The approximate size
and location of the incision (magenta) and the 2 sutures that close the wound
(black) are also shown, along with the area that the von Frey filament was
placed during sensory testing (gray dashed circle). The area of the hind paw
that makes contact with the ground is indicated (green). (B) A paw print image
produced by the Noldus CatWalk software (white box surrounding the paw
print added by the software) from a mouse walking without injury or drug
treatment. Yellow outlines added to A and B indicate the outline of the paw
print captured by the software and the corresponding hind paw anatomy that
generated the print.
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The Noldus CatWalk XT gait analysis system (Noldus Information
Technology, Leesburg, VA) was used to analyze the paw prints of
mice.1,22,31,33,38 In a dark room, mice walked across an elevated
glass platform with a camera positioned underneath, facing the
underside of the animal. Light illuminated the section of the paws
that applied weight on the glass (Fig. 1A). Paw prints were
imaged by the camera and measured using the Noldus CatWalk
XT 10 software (Fig. 1B). The paw print area refers to the total
area of the glass in contact with the paw, measured at the point in
the step when the area of contact with the glass is maximal for
that paw print. Analgesic studies in incision animals were
performed in mice that had a relative paw print area in the
ipsilateral paw that was no greater than 80% than of the
contralateral paw; 10 of 46 mice were thus excluded based on
this criterion.
2.6. Imaging mouse walking behavior
Mice walked across an elevated glass platform and were imaged
with a Google Pixel 4 (Google, Mountain View, CA).
2.7. Statistics
Data were analyzed using GraphPad Prism 9.3.0 (GraphPad
Software, San Diego, CA). Data were analyzed with one-way or
two-way analysis of variance (ANOVA) tests, followed by Dunnett
or Tukey multiple comparisons tests, respectively. When 2
groups were being compared, t tests were used (paired or
unpaired, as indicated below). A simple linear regression was
used to test the correlation between the paw print area and
speed. Statistical values and tests used are described in the text
below. Significant main effects are reported in the text, and
significant post hoc test results are indicated in the figures.

3. Results
3.1. Oxycodone reverses incision-induced mechanical
allodynia but not reduced paw print area of the injured paw
Consistent with prior reports, we find that paw incision produces
robust sensitization to mechanical stimuli in mice as assessed
using von Frey 1 day after injury (Fig. 2A). After treatment with
oxycodone (10 mg/kg, s.c.) on day 1 postsurgery, the withdrawal
thresholds were no longer significantly different from preinjury
baseline values (F6, 60 5 7.097, P , 0.0001, 2-way ANOVA
interaction effect).
Paw incision alters paw placement by inducing paw guarding
behavior in rats and mice.4,41 Therefore, we hypothesized that the
CatWalk gait analysis system, which evaluates paw placement
during walking, would detect altered paw usage in injured mice.
We performed paw incision surgery and analyzed the paw print
area during walking using the CatWalk system 1 day postsurgery.
Paw incision surgery reduced the paw print area of the injured
(ipsilateral) hind paw, relative to the animal’s contralateral paw (P
, 0.0001, paired t test) or to sham animals’ ipsilateral paws (P ,
0.0001, unpaired t test; Fig. 2B). Viewing images of the paw
prints shows that the reduction in the paw print area is due to an
avoidance of placing weight on the proximal section of the paw,
closer to the site of the incision (Fig. 2C).
Next, we assessed if oxycodone could reverse the incisioninduced reduction in the paw print area (Fig. 2D). As in Figure 2B,
the paw print area was reduced in injured hind paws relative to
contralateral paws 1 day postsurgery. We hypothesized that
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oxycodone would increase the contact area of the injured paws.
Surprisingly, however, oxycodone (10 mg/kg) decreased the paw
print area of both uninjured and injured hind paws (F4, 31 5 10.64,
P , 0.0001, 2-way ANOVA interaction effect). In other injury
models, different doses of oxycodone were required to reverse
sensitization phenotypes measured with different behavior
tests.26,40 Therefore, we sought to determine if a lower dose of
oxycodone would reverse the impaired paw placement in the
incised paws without affecting the contralateral paws (Fig. 2E, F).
No dose of oxycodone significantly altered the paw print area of
the injured paw relative to the vehicle (ie, 0 mg/kg of oxycodone)
treatment (Fig. 2E); however, 3 and 10 mg/kg of oxycodone
significantly decreased the area of the contralateral paw prints
relative to the vehicle (F4, 31 5 9.589, P , 0.0001, 1-way ANOVA;
Fig. 2F).

3.2. Opioids dose-dependently decrease the paw print area
during walking
Based on the finding of oxycodone’s effect on the contralateral
paw print area, we further investigated the effect of oxycodone on
paw placement in uninjured mice. Using a range of analgesic
doses of oxycodone,2,14,26,30,39,40 we assessed paw placement
during walking before and after oxycodone treatment, as in
Figure 2D. We found that oxycodone caused dose-dependent
reductions in the print area of the hind paws in both female (F4, 45
5 12.48, P , 0.0001, 2-way ANOVA interaction effect; Fig. 3A)
and male (F4, 40 5 19.86, P , 0.0001, 2-way ANOVA interaction
effect; Fig. 3B) mice, and the effect of oxycodone was greater
than that of vehicle in females (F4, 45 5 11.67, P , 0.0001, oneway ANOVA; Fig. 3C) and males (F4, 40 5 26.65, P , 0.0001,
one-way ANOVA; Fig. 3D), as well. In females, the hind paw print
area was reduced after 3 or 10 mg/kg oxycodone treatment (Fig.
3A), and in males, the hind paw print area was reduced after 1, 3,
or 10 mg/kg oxycodone treatment (Fig. 3B), relative to baseline
print areas. The front paw print area was also significantly
reduced by oxycodone in a dose-dependent fashion in both
females (F4, 45 5 11.27, P , 0.0001, 2-way ANOVA interaction
effect; Fig. 3E) and males (F4, 40 5 7.980, P , 0.0001, 2-way
ANOVA interaction effect; Fig. 3F). Significant reductions relative
to baseline were seen after 3 and 10 mg/kg oxycodone treatment
in both female and male front paw print areas, and, as with the
hind paws, the change in the paw print area induced by
oxycodone was significantly greater than that induced by vehicle
in females (F4, 45 5 7.771, P , 0.0001, one-way ANOVA; Fig. 3G)
and males (F4, 40 5 7.539, P 5 0.0001, one-way ANOVA;
Fig. 3H).
To assess how oxycodone alters paw placement to reduce the
paw print area, we examined paw print images and images of
animals walking after oxycodone treatment. Images of the paw
prints when the maximum contact is made with the glass showed
that mice favored the distal parts (toward the toes) of their feet
after treatment with 10 mg/kg of oxycodone relative to their
walking behavior at baseline (Fig. 4A). While observing mice at
the moment when the hind paw first lands during a step, we saw
that vehicle-treated mice (Fig. 4B) placed their full hind paw pad
down on the glass and that 10 mg/kg oxycodone-treated mice
(Fig. 4C) avoided placing the more proximal section of their paws
(ie, their heels) down on the glass. Oxycodone-treated mice also
showed rigid, vertically pointed tails and, by adopting a tiptoe–like posture while walking, were more elevated from the
platform. The avoidance of heel placement seen after oxycodone
treatment could thus produce a reduction in the paw print area.

4

·

V.E. Brings et al. 7 (2022) e1035

PAIN Reports®

Downloaded from http://journals.lww.com/painrpts by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywC
X1AWnYQp/IlQrHD3i3D0OdRyi7TvSFl4Cf3VC4/OAVpDDa8KKGKV0Ymy+78= on 09/14/2022

Figure 2. Oxycodone reverses mechanical allodynia but not paw print changes after paw incision surgery. (A) Withdrawal threshold was measured in contralateral
and ipsilateral hind paws before paw incision surgery, 1 day after surgery, and 30 minutes after treatment with 10 mg/kg of oxycodone or vehicle on day 1 after
surgery. (B) Paw incision surgery reduced the paw print area of the injured (ipsilateral) hind paw, relative to the animals’ contralateral paw or to sham animals’
ipsilateral paws. (C) View of the hind paw print image collected by the CatWalk system when the paw makes maximum contact with the glass in a paw incision
injured mouse. (D) The paw print area was measured in both hind paws twice on the day after surgery: before (baseline) and after (postdrug) treatment with 10 mg/
kg of oxycodone or vehicle. (E–F) On day 1 after paw incision surgery, the percent change in the paw print area from baseline to postdrug (30 minutes after
treatment with indicated oxycodone doses) in the ipsilateral (E) and contralateral (F) hind paws. All oxycodone administration was s.c., 30 minutes before the
postdrug test. Mean 6 SEM. Showing results of posttests following 2-way ANOVAs for A (P , 0.0001), D (P , 0.0001), and F (P , 0.0001); **P , 0.01, ***P ,
0.001, ****P , 0.0001. (B) Unpaired t test of sham vs incision ipsilateral; paired t test of incision contralateral vs ipsilateral; ****P , 0.0001. ANOVA, analysis of
variance; Con, contralateral; Ipsi, ipsilateral.

To determine if the effect on paw placement found with
oxycodone could be seen with another analgesic mu-opioid
receptor agonist, we examined paw placement on the CatWalk
before and after morphine treatment. Morphine also dosedependently decreased the paw print area. As with oxycodone,
10 mg/kg of morphine (s.c.) reduced the paw print area relative to
baseline (F4, 28 5 2.840, P 5 0.0428, 2-way ANOVA effect of
drug; Fig. 5A, B).
3.3. Altered walking speed does not drive the reduced paw
print area
The oxycodone doses used here significantly increase the
distance covered in an open field,10 and, thus, with time being
a constant, average speed in an open field is increased.
Therefore, we asked whether altered walking speed could cause
the opioid-induced tiptoe like gait. We saw no correlation
between the paw print area and the speed of the mice (Fig.
6A, B).
Nearly all vehicle-treated mice had slower average speeds on
the CatWalk during their postdrug trials relative to their baseline
trials in female mice (F4, 45 5 9.736, P , 0.0001, 2-way ANOVA
interaction effect; Fig. 6C), and both female and male mice (F4, 40
5 6.671, P 5 0.0003, 2-way ANOVA interaction effect; Fig. 6D)
were significantly slower during their post-10 mg/kg of

oxycodone trials relative to baseline, as well. Notably, the
reduction in speed during postdrug trials was significantly greater
in the mice treated with 10 mg/kg of oxycodone relative to the
change in speed in mice treated with the vehicle in both females
(F4, 45 5 12.88, P , 0.0001, one-way ANOVA; Fig. 6E) and males
(F4, 40 5 8.954, P , 0.0001, one-way ANOVA; Fig. 6F).
Interestingly, in female mice, 3 mg/kg of oxycodone increased
walking speed relative to baseline (Fig. 6E). The hind paw print
area was decreased at both 3 and 10 mg/kg of oxycodone in
females (Fig. 3A, C), but speed was increased at 3 mg/kg and
decreased at 10 mg/kg of oxycodone. In addition, the effects of
oxycodone on the hind paw area in males (Fig. 3B, D), particularly
the equivalent effects of 3 and 10 mg/kg on paw placement, did
not match the effects of oxycodone on walking speed (Fig. 6F),
as only 10 mg/kg of oxycodone affected walking speed in male
mice. Together, these data support the conclusion that the
change in speed caused by oxycodone treatment did not drive
the change in paw placement.
As an additional exploration into the effect of walking speed on
paw placement, we tested the effects of 2 nonopioid analgesic
drugs that differentially affect open field activity on the paw print
area in female mice. Fenobam, an mGlu5 receptor negative
allosteric modulator, reduces pain behaviors and increases open
field activity.27 D9-THC, a cannabinoid type 1 and type 2 receptor
agonist, provides antinociception and decreases open field
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Figure 3. Analgesic doses of oxycodone reduce the paw print area in female and male mice. Analgesic doses of oxycodone reduced the hind paw (A–D) and front
paw (E–H) print areas in uninjured female (A, C, E, G) and male (B, D, F, H) mice. (A, B, E, F) The area of the paws at the point of maximum paw contact before
(baseline) and after (postdrug) oxycodone administration. (C, D, G, H) The percent change between baseline and postdrug for each animal. Mean 6 SEM. Showing
results of posttests following 2-way ANOVAs for A (P , 0.0001), B (P , 0.0001), E (P , 0.0001), and F (P , 0.0001) and 1-way ANOVAs for C (P , 0.0001), D (P ,
0.0001), G (P , 0.0001), and H (P 5 0.0001); *P , 0.05, **P , 0.01, ***P , 0.001, ****P , 0.0001. ANOVA, analysis of variance.

activity.3,9,23 Neither fenobam (30 mg/kg, i.p.) nor D9-THC (3 mg/
kg, s.c.) affected the paw print area differently from their vehicletreated counterparts (Fig. 7A, B). Similarly to the oxycodone-

treated mice, the effects on speed also did not match their
respective effects on previously reported open field activity.
Fenobam and vehicle treatment had equivalent effects on speed

6

·

V.E. Brings et al. 7 (2022) e1035

PAIN Reports®

Downloaded from http://journals.lww.com/painrpts by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywC
X1AWnYQp/IlQrHD3i3D0OdRyi7TvSFl4Cf3VC4/OAVpDDa8KKGKV0Ymy+78= on 09/14/2022

Figure 5. Analgesic doses of morphine reduce the hind paw print area during
walking in female mice. (A) The area of the hind paws at the point of maximum
paw contact before (baseline) and after (postdrug) morphine administration
(s.c., 30 minutes before test). (B) The percent change in the paw print area
between baseline and postdrug for each animal. Mean 6 SEM. Showing
results of posttests following a 2-way ANOVA for A (P 5 0.0428); *P , 0.05.
ANOVA, analysis of variance.

Figure 4. Analgesic doses of oxycodone reduce the paw print area by inducing
tiptoe walking. (A) Paw prints were imaged by the Noldus CatWalk software.
White boxes show edges of the paw print. Mice were photographed while
walking on an elevated glass platform 30 minutes after treatment with vehicle
(B) or 10 mg/kg of oxycodone (C). The oxycodone-treated mouse shows
incomplete placement of the hind paw on the glass, elevated body position
relative to the platform, and a rigid Straub tail.

(Fig. 7C), and mice treated with D9-THC did not have the same
reductions in walking speed as the vehicle-treated mice (P 5
0.0192, unpaired t test; Fig. 7D).

4. Discussion
Overall, we found that paw incision surgery reduced contact of
the incised section of the paw during walking on the CatWalk
platform, resulting in a decrease in the paw print area of the
injured hind paw. Treatment with analgesic doses of opioids
induced a tiptoe like gait in injured and uninjured mice, causing

reduced paw print area of both hind paws. Therefore, although
the paw print area during walking may be used to as a phenotypic
demonstration of postinjury sensitization, it is not one that can be
reversed by opioids in mice, as opioid treatment presents a
confounding phenotype.
Within the results showing that opioids induce tiptoe walking,
notable differences were seen between some subgroups. At the
same doses, morphine had smaller effects on the paw print area
(Fig. 5A, B) than oxycodone did (Fig. 3A, C). Others have
observed similar differences, as morphine has also been shown
to be less analgesic in injured mice and has reduced antinociceptive efficacy in uninjured mice, relative to the same doses of
oxycodone.26,30 In addition, females and males responded
differently to the same oxycodone doses. In males, 1 mg/kg of
oxycodone reduced the hind paw print area relative to baseline
(Fig. 3B), whereas females were only affected at a dose as low as
3 mg/kg of oxycodone (Fig. 3A). The sex differences in the effects
of oxycodone on the paw print area echo the literature
demonstrating the enhanced sensitivity of male mice to the
effects of opioids relative to female mice, including opioidinduced antinociception, tolerance, and locomotor activity.7,10,24
In addition to the effects of opioids on the paw print area, this
work demonstrates an effect on walking speed that has not
previously been quantified. Here, we show that male and female
mice have a greater decrease in walking speed after treatment
with 10 mg/kg of oxycodone than their vehicle-treated counterparts (Fig. 6C–F). This dose of oxycodone was previously
reported to increase the total distance traveled in an open field
in both sexes.10 An increase in distance traveled is typically
interpreted as an increase in average speed for the whole
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Figure 7. Nonopioid analgesics fenobam and D9-THC do not affect the paw
print area. The percent change in the hind paw area (A and B) and average
walking speed (C and D) between baseline and postdrug walking in mice
treated with (A and C) fenobam (30 mg/kg, i.p., 5 minutes before test) and (B
and D) D9-THC (3 mg/kg, s.c., 30 minutes before test). Mean 6 SEM. Unpaired
t test in D; *P , 0.05.

Figure 6. Oxycodone’s effect on walking speed does not drive altered paw
print area. Speed and front or hind paw print area had no correlation in
oxycodone-treated female (A) or male (B) mice. The average speed during
walking on the CatWalk platform before (baseline) and after (postdrug)
oxycodone administration in females (C) and males (D). The percent change
between baseline and postdrug for each female (E) and male (F) mouse.
Showing results of linear regression for A and B and posttests following 1-way
ANOVAs for C (P , 0.0001), D (P 5 0.0003), E (P , 0.0001), and F (P ,
0.0001); *P , 0.05, **P , 0.01, ****P , 0.0001. (C–F) Mean 6 SEM. ANOVA,
analysis of variance.

experiment, as the time of an open field test is kept constant.
However, mice spend large portions of the open field period
immobile. Our results suggest that the 10 mg/kg oxycodoneinduced increase in distance covered may instead be driven by an
increase in the percent of time spent mobile, with the walking
speed (the average speed during mobile periods, not during the
whole course of the test) actually being lower than that of vehicletreated mice. An increase in the percent of time spent walking
would also lead to more distance covered, a result that is often
interpreted as being due to faster walking. As researchers explore
the side effects of opioids in mice, including locomotor
sensitization, our results on the effects of oxycodone on speed
may help people better evaluate their data. Similar differential
effects were shown here for THC and fenobam; the average
walking speed in CatWalk did not align with the average speed
previously shown in an open field, as calculated using the total
distance covered. CatWalk and open field experiments have
different conditions (eg, floor material and lighting) that could

contribute to different walking behaviors in each type of arena, but
it would be interesting to parse out the effects on walking speed
and time spent walking in an open field after treatment with these
drugs as well.
One other mouse model that has shown tiptoe walking is the
twy Yoshimura mouse, but the cause of tiptoe walking in this
animal is a spinal injury arising from spinal ligament ossification
and is unlikely to share a causal mechanism with acute opioidinduced tiptoe gait.18 Others have anecdotally noted the
presence of tiptoe like walking induced by buprenorphine,20,21
but none have quantified this behavior, and the cause is
unknown.
One known side effect of mu-opioid receptor agonist
treatment that could cause altered paw placement is muscle
rigidity. Rigid extension of the hind limbs resulting from
subcutaneous morphine has been noted in mice6 and was
quantified in hind limb electromyographic activity studies using
rats treated with subcutaneous alfentanil. 37 Muscle stiffness in
the hind limbs could cause the back legs to be extended
backward, preventing the heels of the hind paw from making
contact with the walking surface, leading to a reduced hind
paw print area. At higher oxycodone doses, this rigid extension
may also occur in the fore limbs, leading to the reduced paw
print area seen in the front paws. Similarly, muscle rigidity is
seen in the tail (ie, Straub tail) in a dose-dependent fashion6
that correlates well with the dose-dependent effect of tiptoe
walking (Fig. 4C), supporting the potential conclusion that
muscle rigidity drives this effect.
An interesting effect on speed is seen in females treated with
oxycodone; compared with their baseline speed, postdrug
walking speed dose dependently increases with oxycodone
treatment up to 3 mg/kg but is significantly decreased with 10
mg/kg of oxycodone. If muscle rigidity begins between 3 and 10
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mg/kg in females, perhaps the hyperlocomotion effect of
oxycodone begins to be outweighed by the muscle rigidity effect
at doses above 3 mg/kg. In other words, oxycodone may dosedependently increase the drive to be mobile (hence the increase
in open field distance covered at 10 mg/kg10), but by 10 mg/kg,
the muscle rigidity effect is strong enough to slow down the
walking speed so that the mice are not walking faster, they are
simply walking for longer.
Ideally, there would be a dose of oxycodone that would provide
analgesia in incised animals without inducing tiptoe walking.
Indeed, the effective dose of oxycodone can vary for different
phenotypes of a single injury model; for example, in a mouse
model of burn pain, the oxycodone dose required to reverse
injury-induced CatWalk phenotypes was higher than the dose
required to reverse injury-induced von Frey effects.40 However, in
the paw incision mice tested here, the oxycodone doses that
were low enough not to affect the paw print area in uninjured
paws were not sufficient to reverse the paw print area phenotype
in injured hind paws. The dose range at which analgesia is
typically provided by oxycodone (1–20 mg/kg)2,14,26,30,39,40
overlaps with the dose range for tiptoe walking shown here
(1–10 mg/kg; Fig. 3). Therefore, although the paw print area is a
robust metric for demonstrating gait alterations induced by paw
incision, this metric cannot be used to evaluate oxycodone’s
ability to provide analgesia in this injury model.
Additional assessments are needed to confirm that the
incision-induced paw print area reductions are indeed a painrelated phenotype. Opioid treatment was shown to reverse paw
usage impairments (guarding behavior) caused by paw incision41
and paw print area changes induced by other injury models1,41 in
rats. Furthermore, the paw print area changes induced by
neuropathic injury were reversed by gabapentin in mice.22 This
suggests that altered paw placement is indeed a pain-related
symptom that can be reversed by analgesics in rodents.
As a future direction, other metrics of paw usage could be
analyzed to determine if they are altered by paw incision surgery
and/or opioid treatment in mice. Whereas the CatWalk system
measures 2-dimensional paw placement, the amount of weight
placed on the paw can only be generally estimated based on the
light intensity of the paw print. Oxycodone may not reverse the
area of the injured paw that makes contact with the glass, but it
may affect how much weight is being placed on that reduced foot
print. Static or dynamic weight-bearing assays may be used as an
alternative method to find a paw usage phenotype that is altered
in an injured state and reversed by oxycodone. Having a better
understanding of how paw usage varies with injury or oxycodone
treatment, as well as how paw usage phenotypes manifest on
test surfaces made of different materials, would also help
determine if other paw-directed assays (eg, hot plate) are indeed
appropriate to use in these contexts.
These results have interesting implications for how behavioral
effects of opioids are studied in mice, including analgesia, muscle
rigidity, and locomotion. Alternatives to hind paw–directed
reflexive assays for testing opioid analgesia, particularly in a
postsurgical pain model, are still needed, but analysis of paw
placement during walking may be an interesting area to look for
new approaches. Overall, this research will help refine approaches to evaluating opioids in preclinical research, particularly
when applied to mouse pain models.
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